2. National Comprehensive Cancer Network: Prostate Cancer (Version 1.2023), 2023 https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

3. Roehl K.A., Han M., Ramos C.G., Antenor J.A., Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol. 2004;172:910–914. Doi: 10.1097/01.ju.0000134888.22332.bb. .

4. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J.,Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439. Doi: 10.1001/jama.294.4.433. PMID: 16046649.

5. Artibani W., Porcaro A.B., De Marco V., Cerruto M.A., Siracusano S. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100:251–262. Doi: 10.1159/000481438. Epub 2017 Nov 21. PMID: 29161715.

6. Barlow S.K., Oyekunle T., Janes J.L., De Hoedt A.M., Aronson W.J., Kane C.J., et al. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. Prostate. 2022;82:366–372. Doi: 10.1002/pros.24283.

7. Phillips R. Prostate cancer: post-treatment complications of radiotherapy and prostatectomy. Nat Rev Urol. 2014;11(3):129. Doi: 10.1038/nrurol.2014.18. Epub 2014 Feb 4. PMID: 24492436.

8. Patel P, Lee WR. Radiotherapy following radical prostatectomy. Expert Rev Anticancer Ther. 2012;12(7):973–979. Doi: 10.1586/era.12.66.

9. Stephenson A.J., Scardino P.T., Kattan M.W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035–2041. Doi: 10.1200/JCO.2006.08.9607. PMCID: PMC2670394.

10. Thompson I.M., Valicenti R.K., Albertsen P., Davis B.J., Goldenberg S.L., Hahn C., et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline J Urol. 2013;190:441–449.

11. Bolla M., van Poppel H., Tombal B., Vekemans K., Da Pozzo L., de Reijke T.M.,et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911) Lancet. 2012;380:2018–2027.

12. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow up of a randomized clinical trial J Urol. 2009;181:956–962. Doi: 10.1016/j.juro.2013.05.032.

13. Wiegel T., Bottke D., Steiner U., Siegmann A., Golz R., Storkel S., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pt3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27(18):2924–2930. Doi: 10.1200/JCO.2008.18.9563.

14. Sineshaw H.M., Gray P.J., Efstathiou J.A., Jemal A. Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. Eur Urol. 2015;68(5):768–774. Doi: 10.1016/j.eururo.2015.04.003.

15. King C.R. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104–111. Doi: 10.1016/j.ijrobp.2011.10.069.

16. Fossati N., Karnes R.J., Cozzarini C., Fiorino C., Gandaglia G., Joniau S., et al. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2016;69(4):728–733. Doi: 10.1016/j.eururo.2015.10.009.

17. Tendulkar R.D., Agrawal S., Gao T., Efstathiou J.A., Pisansky T.M., Michal-ski J.M., et al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016;34(30):3648–3654. Doi: 10.1200/JCO.2016.67.9647.

18. Parker C.C., Clarke N.W., Cook A.D., et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413–1421. Doi: 10.1016/S0140-6736(20)31553-1.

19. Sargos P., Chabaud S., Latorzeff I., et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341–1352. Doi: 10.1016/S1470-2045(20)30454-X. PMID: 33002438.

20. Kneebone A., Fraser-Browne C., Duchesne G.M., et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21(10):1331–1340. Doi: 10.1016/S1470-2045(20)30456-3. PMID: 33002437.

21. Vale C.L., Fisher D., Kneebone A., et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422–1431. Doi: 10.1016/S0140-6736(20)31952-8.

22. Cornford P., Bellmunt J., Bolla M., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71(4):630–642. Doi: 10.1016/j.eururo.2016.08.002.

23. Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002 Jun;56(6):779–786. Doi: 10.1046/j.1365-2265.2002.01551.x.

24. Van den bergh R.C., van Casteren N.J., van den Broeck T., et al. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol. 2016;69(5):802–820. Doi: 10.1016/j.eururo.2015.11.023.

25. Garcia-Albeniz X., Chan J.M., Paciorek A., et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015;51(7):817–824. Doi: 10.1016/j.ejca.2015.03.003.

26. Duchesne G.M., Woo H.H., Bassett J.K., et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03

27. Antonarakis E.S., Feng Z., Trock B.J., et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109(1):32–39. Doi: 10.1111/j.1464-410X.2011.10422.x.

28. Virgo K.S., Rumble R.B., de Wit R., et al. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(11):1274–1305. Doi: 10.1200/JCO.20.03256.

29. Lowrance WT, Breau RH, Chou R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021;205(1):14–21. Doi: 10.1097/JU.0000000000001375.

30. Van den Broeck T., van den Bergh R.C.N,. Arfi N., et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019 Jun;75(6):967–987. Doi: 10.1016/j.eururo.2018.10.011.

31. Klotz L. The history of intermittent androgen deprivation therapy – A Canadian story. Can Urol Assoc J. 2020 Jun;14(6):159–162. Doi: 10.5489/cuaj.6601.

32. Giraud N., Benziane-Ouaritini N., Schick U., et al. Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach? Front Oncol. 2021;11:781040. Doi: 10.3389/fonc.2021.781040.

33. Gazta~naga M, Crook JM. Permanent seed brachytherapy for locally recurrent prostate cancer after radical prostatectomy: a case report and review of the literature. Brachytherapy. 2013;12(4):338–342. doi: 10.1016/j.brachy.2012.04.006.

34. Hosogoe S., Soma O., Matsumoto T., et al. Salvage Brachytherapy for Castration-Resistant and External Beam Radiotherapy-Resistant Local Recurrence 17 Years after Radical Prostatectomy. Case Rep Urol. 2015;2015:839738. Doi: 10.1155/2015/839738.

35. Niehoff P., Loch T., Nurnberg N. et al. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Brachytherapy. 2005;4(2):141–145. Doi: 10.1016/j.brachy.2004.12.004.

36. Losa A., Nava L.D., Di Muzio N et al. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology. 2003;62(6):1068–1072. Doi: 10.1016/s0090-4295(03)00784-2.

37. Gaztanaga M., Crook J.M. Permanent seed brachytherapy for locally recurrent prostate cancer after radical prostatectomy: a case report and review of the literature. Brachytherapy. 2013;12(4):338–342. Doi: 10.1016/j.brachy.2012.04.006.

38. Gomez-Veiga F., Marino A., Alvarez L. et al. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int. 2012;109(Suppl 1):17–21. Doi: 10.1111/j.1464-410X.2011.10826.x.

39. Strom T.J., Wilder R.B., Fernandez D.C., et al. High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy. Brachytherapy. 2014;13(2):123–127. Doi: 10.1016/j.brachy.2013.09.008.

40. Kumar A.M.S., Smith K.L., Reddy C.A., et al. Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy. J Contemp Brachytherapy. 2015;7(4):241–246. Doi: 10.5114/jcb.2015.54050.

41. Buchser D., Gomez-Iturriaga A., Melcon J.I., et al. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. J Contemp Brachytherapy. 2016;8(6):477–483. Doi: 10.5114/jcb.2016.64441.

42. Solodkiy V.A., Pavlov A.Yu., Tsybulskiy A.D., Dzidzariya A.G., Pchelintsev A.S.Salvage high dose-rate brachytherapy for local recurrence of prostate cancer after different types of radical treatment. Cancer Urology. 2019;15(2):73–76.Russian (Солодкий В.А., Павлов А.Ю., Цыбульский А.Д. Спасительная брахитерапия высокой мощности дозы при локальном рецидиве рака предстательной железы. ЭКУ. 2017. № 4) https://doi.org/10.17650/1726-9776-2019-15-2-73-76

43. Yagudaev D.M., Kadyrov Z.A., Kalinin M.R., Bezhenar V.A., Kalyagina N.A.Salvage high-dose-rate brachytherapy for local recurrence of prostate cancer. Cancer Urology. 2018;14(2):171–175. Russian (Ягудаев Д.М.,Кадыров З.А., Калинин М.Р., Беженар В.А., Калягина Н.А. Спасительная высокодозная брахитерапия при локальном рецидиве рака предстательной железы. Онкоурология. 2018;14(2):171–175) https://doi.org/10.17650/1726-9776-2018-14-2-171-175

44. Solodkiy V.A., Pavlov A.Yu., Tsybulskiy A.D., Dzidzariya A.G., Pchelintsev A.S. Salvage high dose-rate brachytherapy for local recurrence of prostate cancer after different types of radical treatment. Cancer Urology. 2019;15(2):73–76. Russian (Солодкий В.А., Павлов А.Ю., Цыбульский А.Д., Дзидзария А.Г., Пчелинцев А.С. Спасительная брахитерапия высокой мощности дозы при локальном рецидиве рака предстательной железы после различных методов радикального лечения. Онкоурология. 2019;15(2):73–76) https://doi.org/10.17650/1726-9776-2019-15-2-73-76

45. Kaprin A.D., Ivanov S.A., Karyakin O.B., Obuhov A.A., Biryukov V.A.,Borysheva N.B., Sanin D.B., Lepilina O.G., Smolkin A.L., Dem’yanovich A.V.,Minaeva N.G., Mikhaylovskiy N.V. Salvage high-dose-rate brachytherapy for recurrent prostate cancer. Cancer Urology. 2020;16(4):112–119. Russian (Каприн А.Д., Иванов С.А., Карякин О.Б., и др., Спасительная высокомощностная брахитерапия рецидива рака предстательной железы. Онкоурология. 2020;16(4):112–119). https://doi.org/10.17650/1726-9776-2020-16-4-112-119

46. Hennequin C., Hannoun-Lévi J.M., Rozet F.Management of local relapse after prostate cancer radiotherapy: Surgery or radiotherapy? Cancer Radiother. 2017;21(6-7):433–436. Doi: 10.1016/j.canrad.2017.07.026. Epub 2017 Sep 7. PMID: 28890088.

47. Siddiqui S.A., Mynderse L.A., Zincke H. et al. Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience. Urology. 2007;70(1):80–85. Doi: 10.1016/j.urology.2007.03.002. PMID: 17656213.

48. Asimakopoulos AD, Miano R, Virgili G et al. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study. Urol Oncol. 2012;30(5):577–583. Doi: 10.1016/j.urolonc.2010.08.019.

49. Murota-Kawano A., Nakano M., Hongo S. et al. Salvage high-intensity focused ultrasound for biopsy-confirmed local recurrence of prostate cancer after radical prostatectomy. BJU Int. 2010;105(12):1642–1645. Doi: 10.1111/j.1464-410X.2009.08990.x.